Current status of catheter- and stent-based gene therapy.
Significant progress has been made in the field of cardiovascular gene therapy over the past decade. Animal models of human disease have helped in identifying potential therapeutic genes and have also assisted in the evaluation of an ideal vector. A number of percutaneous catheter systems have been used in animal models with limited success. Stents represent an attractive alternative for localized gene delivery, as they provide a platform for prolonged gene elution and efficient transduction of opposed arterial walls. This gene delivery strategy has the potential to decrease the systemic spread of the viral vectors and hence a reduced host immune response. Both synthetic and naturally occurring stent coatings have shown potential to allow prolonged gene elution with no significant adverse reaction. However, further animal studies are required to evaluate the compatibility of stent coatings, vector solutions, and the arterial wall as well as assessment of the feasibility of this approach to achieve the full potential of gene therapy.
Sharif
F
F
National Centre of Biomedical Engineering and Science, National University of Ireland, University Rd., Galway, Ireland. Faisalshareef@yahoo.com
Daly
K
K
Crowley
J
J
O'Brien
T
T
D000818:Animals; D001161:Arteriosclerosis / Q000628:therapy*; D019917:Blood Vessel Prosthesis Implantation; D002404:Catheterization; D020099:Coated Materials, Biocompatible; D015870:Gene Expression; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000008:administration & dosage; D006801:Humans; D023421:Models, Animal; D015607:Stents
D020099:Coated Materials, Biocompatible